Literature DB >> 7073356

The importance of early diagnosis in patients with hereditary medullary thyroid carcinoma.

S A Wells, S B Baylin, G S Leight, J K Dale, W G Dilley, J R Farndon.   

Abstract

Ninety-two patients from 12 kindreds with hereditary medullary thyroid carcinoma (MTC) were evaluated. We sought to determine if the stimulated plasma calcitonin (CT) level at the time of diagnosis was of prognostic significance. The patients were divided into four groups according to their preoperative stimulated plasma CT levels (1) 250-1,000 pg/ml (n=25); (2) 1,000-5,000 pg/ml (n=36); (3) 5,000-10,000 pg/ml (n=8); (4) greater than 10,000 pg/ml (n=23). Compared between the four groups were several parameters, including incidence of regional lymph node metastases, incidence of residual MTC post-thyroidectomy (as indicated by increased (greater than 300 pg/ml) plasma CT levels after operation), incidence of distant metastases, and incidence of death. Also compared were the incidences of microscopic or gross MTC in thyroidectomy specimens. The incidence of regional lymph node involvement ranged from a minimum of one (4%) of 25 patients in Group 1 to 13 (57%) of 23 patients in Group 4. Similarly, plasma CT levels were elevated in only one (4%) of 25 patients in Group 1 compared to 14 (61%) of 23 patients in Group 4. There was no evidence of distant metastases or death in the patients in Groups 1, 2, or 3. In the 23 patients in group 4, however, four (17.4%) had distant metastases and two (8.7%) died of disease during the period of observation. Of th 25 patients in Group 1, MTC was evident only by microscopic examination in 14 (56%). Eleven (44%) of the patients in Group 1 had macroscopically evident medullary thyroid carcinoma. This is in contrast with patients in Group 4 where all 23 had grossly evident MTC. These data indicate that the stimulated plasma CT level at the time of diagnosis is an excellent prognostic indicator of the extent of a disease in patients with hereditary MTC. Aggressive screening of kindred members at risk is of critical importance for establishing the diagnosis and instituting therapy at a time when the neoplasm is confined to the thyroid gland.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7073356      PMCID: PMC1352565          DOI: 10.1097/00000658-198205000-00008

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  8 in total

1.  Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity.

Authors:  J B HAZARD; W A HAWK; G CRILE
Journal:  J Clin Endocrinol Metab       Date:  1959-01       Impact factor: 5.958

2.  Multiple endocrine neoplasia type IIb: the most aggressive form of medullary thyroid carcinoma.

Authors:  J A Norton; L C Froome; R E Farrell; S A Wells
Journal:  Surg Clin North Am       Date:  1979-02       Impact factor: 2.741

3.  A comparison of pentagastrin injection and calcium infusion as provocative agents for the detection of medullary carcinoma of the thyroid.

Authors:  J F Hennessy; S A Wells; D A Ontjes; C W Cooper
Journal:  J Clin Endocrinol Metab       Date:  1974-09       Impact factor: 5.958

4.  Immunoassay of human calcitonin.

Authors:  A H Tashijan; B G Howland; K E Melvin; C S Hill
Journal:  N Engl J Med       Date:  1970-10-22       Impact factor: 91.245

5.  Natural history of familial medullary thyroid carcinoma: effect of a program for early diagnosis.

Authors:  K Graze; I J Spiler; A H Tashjian; K E Melvin; S Cervi-Skinner; R F Gagel; H H Miller; H J Wolfe; R A DeLellis; L Leape; Z T Feldman; S Reichlin
Journal:  N Engl J Med       Date:  1978-11-02       Impact factor: 91.245

6.  Calcitonin and histaminase in C-cell hyperplasia and medullary thyroid carcinoma. A light microscopic and immunohistochemical study.

Authors:  G Mendelsohn; J C Eggleston; W R Weisburger; D S Gann; S B Baylin
Journal:  Am J Pathol       Date:  1978-07       Impact factor: 4.307

7.  Medullary thyroid carcinoma: relationship of method of diagnosis to pathologic staging.

Authors:  S A Wells; S B Baylin; D S Gann; R E Farrell; W G Dilley; S H Preissig; W M Linehan; C W Cooper
Journal:  Ann Surg       Date:  1978-09       Impact factor: 12.969

8.  Provocative agents and the diagnosis of medullary carcinoma of the thyroid gland.

Authors:  S A Wells; S B Baylin; W M Linehan; R E Farrell; E B Cox; C W Cooper
Journal:  Ann Surg       Date:  1978-08       Impact factor: 12.969

  8 in total
  11 in total

1.  99mTc(V)-dimercaptosuccinic acid scintigraphy for medullary thyroid carcinoma.

Authors:  A Miyauchi; K Endo; H Ohta; K Torizuka; F Matsuzuka; A Kobayashi; K Kuma; M Maeda
Journal:  World J Surg       Date:  1986-08       Impact factor: 3.352

2.  Medullary thyroid carcinoma in Northern Ireland, 1967-1997.

Authors:  S J Dolan; C F Russell
Journal:  Ann R Coll Surg Engl       Date:  2000-05       Impact factor: 1.891

3.  Evaluation of surgical results and prediction of prognosis in patients with medullary thyroid carcinoma by analysis of serum calcitonin levels.

Authors:  A Miyauchi; F Matsuzuka; K Kuma; S Takai; K Nakamoto; K Nakamura; S Nanjo; M Maeda
Journal:  World J Surg       Date:  1988-10       Impact factor: 3.352

4.  Screening for familial medullary thyroid carcinoma: a review.

Authors:  B A Ponder
Journal:  J R Soc Med       Date:  1984-07       Impact factor: 5.344

5.  Surgical treatment strategy for thyroid gland carcinoma nodal metastases.

Authors:  J Betka; L Mrzena; J Astl; J Nemec; P Vlcek; M Taudy; J Skrivan
Journal:  Eur Arch Otorhinolaryngol       Date:  1997       Impact factor: 2.503

Review 6.  The role of prophylactic surgery in cancer prevention.

Authors:  Y Nancy You; Vipul T Lakhani; Samuel A Wells
Journal:  World J Surg       Date:  2007-03       Impact factor: 3.352

Review 7.  Systemic Therapy in Thyroid Cancer.

Authors:  Amit Kumar Agrawal; Vanita Noronha; Vijay Patil; Nandini Menon; Akhil Kapoor; Anuradha Chougule; Pratik Chandrani; Kumar Prabhash
Journal:  Indian J Surg Oncol       Date:  2021-08-19

8.  Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma.

Authors:  A Miyauchi; T Onishi; S Morimoto; S Takai; F Matsuzuka; K Kuma; M Maeda; Y Kumahara
Journal:  Ann Surg       Date:  1984-04       Impact factor: 12.969

9.  Preliminary report of a kindred affected from MEN IIa.

Authors:  A Libroia; C Cremoncini; C Valente; F Silvestrini; B Palmieri; F Romani; F Zurleni; L Belli
Journal:  J Endocrinol Invest       Date:  1984-10       Impact factor: 4.256

10.  Improved predictive test for MEN2, using flanking dinucleotide repeats and RFLPs.

Authors:  J R Howe; T C Lairmore; S K Mishra; S Dou; R Veile; S A Wells; H Donis-Keller
Journal:  Am J Hum Genet       Date:  1992-12       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.